Tuberculosis cost-effectiveness of therapy: Difference between revisions
Mohamed riad (talk | contribs) |
|||
| (11 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Tuberculosis}} | {{Tuberculosis}} | ||
{{CMG}} ; {{AE}} {{Ammu}} | {{CMG}} ; {{AE}} {{Mashal Awais}}; {{Ammu}} | ||
==Overview== | ==Overview== | ||
[[Tuberculosis]] [[treatment]] must be evaluated for relative cost-effectiveness of [[inpatient]] and [[outpatient]] models of [[Care centers|care]] as it will benefit regions where [[tuberculosis]] is [[Endemic (epidemiology)|endemic]]. It is highly recommended to treat the [[Tuberculosis|TB]] patient in [[ambulatory care]] instead of [[inpatient]] setting unless there are severe [[Complication (medicine)|complications]].<ref name="pmid22070215">{{cite journal| author=Fitzpatrick C, Floyd K| title=A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. | journal=Pharmacoeconomics | year= 2012 | volume= 30 | issue= 1 | pages= 63-80 | pmid=22070215 | doi=10.2165/11595340-000000000-00000 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22070215 }} </ref> | |||
==Cost effectiveness of therapy== | ==Cost effectiveness of therapy== | ||
While measurements of morbidity and mortality are | While measurements of morbidity and mortality are important considerations for estimating the burden of disease in populations, they give an incomplete picture of the adverse effect of sickness on human welfare especially the economic consequences of poor health that may be substantial. | ||
Analysis of the economic | Analysis of the economic effect of the disease addresses multiple policy questions regarding the results of disease. Some of these questions are associated with the microeconomic level of households, firms, or government – such as the effect of the disease on a household’s income or a firm’s profits – while others relate to the macroeconomic level, including the cumulative effect of a disease on a country’s currency and future gross domestic product (GDP). | ||
WHO | [[World Health Organization|WHO]] suggests a outlined conceptual framework within which the economic burden of diseases and injuries can be appropriately estimated. <ref name="WHO">{{cite web | title = Cost-effectiveness and strategic planning| url = http://www.who.int/choice/economicburden/en/ }}</ref> | ||
The cost | The cost of the current regimen is approximately 4000 US$ per patient excluding laboratory, human resource, and patient opportunity costs. <ref name="Cost">{{cite web | title = Cost effectiveness purposed by WHO| url = http://www.who.int/bulletin/volumes/92/1/13-122028/en/}}</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 500px;" align=center | |||
|valign=top| | The cost-effectiveness in various tubercular control interventions in Africa region is given below. <ref name="Cost">{{cite web | title = Cost effectiveness with TB control interventions| url = http://www.who.int/choice/publications/p_2005_MDG_series_TB.pdf?ua=1}}</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 500px;" align="center" | |||
| valign="top" | | |||
|+ | |+ | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Intervention}} | ! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Intervention}} | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Yearly costs with 95% coverage level}} | ! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Yearly costs with 95% coverage level}} | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Minimal DOTS | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Minimal DOTS | ||
| style="padding: 5px 5px; background: #F5F5F5;" | 366.3 million $ | | style="padding: 5px 5px; background: #F5F5F5;" |366.3 million $ | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Full DOTS | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Full DOTS | ||
| Line 35: | Line 38: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category: Pulmonology]] | |||
[[Category:Pulmonology | |||
[[Category:Bacterial diseases]] | [[Category:Bacterial diseases]] | ||
Latest revision as of 05:22, 27 March 2021
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberculosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Tuberculosis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Tuberculosis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Mashal Awais, M.D.[2]; Ammu Susheela, M.D. [3]
Overview
Tuberculosis treatment must be evaluated for relative cost-effectiveness of inpatient and outpatient models of care as it will benefit regions where tuberculosis is endemic. It is highly recommended to treat the TB patient in ambulatory care instead of inpatient setting unless there are severe complications.[1]
Cost effectiveness of therapy
While measurements of morbidity and mortality are important considerations for estimating the burden of disease in populations, they give an incomplete picture of the adverse effect of sickness on human welfare especially the economic consequences of poor health that may be substantial.
Analysis of the economic effect of the disease addresses multiple policy questions regarding the results of disease. Some of these questions are associated with the microeconomic level of households, firms, or government – such as the effect of the disease on a household’s income or a firm’s profits – while others relate to the macroeconomic level, including the cumulative effect of a disease on a country’s currency and future gross domestic product (GDP).
WHO suggests a outlined conceptual framework within which the economic burden of diseases and injuries can be appropriately estimated. [2]
The cost of the current regimen is approximately 4000 US$ per patient excluding laboratory, human resource, and patient opportunity costs. [3]
The cost-effectiveness in various tubercular control interventions in Africa region is given below. [3]
| Intervention | Yearly costs with 95% coverage level |
|---|---|
| Minimal DOTS | 366.3 million $ |
| Full DOTS | 612.2 million $ |
| Minimal DOTS with resistant cases | 495.9 million $ |
| Full combination | 739.4 million $ |
References
- ↑ Fitzpatrick C, Floyd K (2012). "A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis". Pharmacoeconomics. 30 (1): 63–80. doi:10.2165/11595340-000000000-00000. PMID 22070215.
- ↑ "Cost-effectiveness and strategic planning".
- ↑ 3.0 3.1 "Cost effectiveness purposed by WHO".